Genome Sequencing in Cancer Research and Therapy

Stefan Fröhling has a long-standing interest in identifying genetic abnormalities that define disease subgroups and treatment outcome in patients with acute myeloid leukemia. Furthermore, he works to identify new cancer drug targets through a better understanding of the functional dependencies of hematologic and solid-organ malignancies, and to bring targeted approaches and molecularly based patient stratification to clinical trials and patient treatment broadly across tumor types. He has been an investigator in 31 clinical trials (phase I-III) and currently acts as the Leading Coordinator of the international AMLSG 23-14/Palbo-AL-1 Trial (Phase Ib/IIa Study of Palbociclib in MLL-Rearranged Acute Leukemias; EudraCT: 2014-003647-34; investigator-initiated trial) and as Co-Investigator of the NOPASS Trial (Phase II Window-of-Opportunity Study of Preoperative Therapy With Pazopanib in High-Risk Soft-Tissue Sarcoma; EudraCT: 2011-003745-18; investigator-initiated trial) and the BRF117019 Trial (Phase II, Open-Label Study in Subjects with BRAF V600E-Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy And Safety of the Combination Therapy of Dabrafenib and Trametinib; EudraCT: 2013-001705-87). Stefan Fröhling serves as an Attending Physician in the Department of Translational Oncology at NCT and is an Investigator within NCT MASTER, where he is responsible for the NCT Precision Oncology Tumor Board. In his presentation he presents the cutting research of employing genome sequencing in translational cancer research, from "bench to bedside and back".